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Abstract
Background: Noninvasive ventilation (NIV) is indicated to treat respiratory acidosis due to exacerbation of chronic
obstructive pulmonary disease (COPD). Recent nonrandomized studies also demonstrated some physiological
effects of high-flow nasal therapy (HFNT) in COPD patients. We designed a prospective, unblinded, multicenter,
randomized controlled trial to assess the noninferiority of HFNT compared to NIV with respect to the reduction of
arterial partial pressure of carbon dioxide (PaCO2) in patients with hypercapnic acute respiratory failure with mild-to-
moderate respiratory acidosis.
Methods: We will enroll adult patients with acute hypercapnic respiratory failure, as defined by arterial pH between
7.25 and 7.35 and PaCO2 ≥ 55 mmHg. Patients will be randomly assigned 1:1 to receive NIV or HFNT. NIV will be
applied through a mask with a dedicated ventilator in pressure support mode. Positive end-expiratory pressure will
be set at 3–5 cmH2O with inspiratory support to obtain a tidal volume between 6 and 8 ml/kg of ideal body
weight. HFNT will be initially set at a temperature of 37 °C and a flow of 60 L/min. At 2 and 6 h we will assess
arterial blood gases, vital parameters, respiratory rate, treatment intolerance and failure, need for endotracheal
intubation, time spent under mechanical ventilation (both invasive and NIV), intensive care unit and hospital length
of stay, and hospital mortality.
Based on an α error of 5% and a β error of 80%, with a standard deviation for PaCO2 equal to 15 mmHg and a
noninferiority limit of 10 mmHg, we computed a sample size of 56 patients. Considering potential drop-outs and
nonparametric analysis, the final computed sample size was 80 patients (40 per group).
Discussion: HFNT is more comfortable than NIV in COPD patients recovering from an episode of exacerbation. If
HFNT would not be inferior to NIV, HFNT could be considered as an alternative to NIV to treat COPD patients with
mild-to-moderate respiratory acidosis.
Trial registration: ClinicalTrials.gov, NCT03370666. Registered on December 12, 2017.
Keywords: High-flow oxygen therapy through nasal cannula, Noninvasive ventilation, Chronic obstructive pulmonary
disease, Carbon dioxide, Acute respiratory failure, Intensive care unit, Emergency department
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Background
Severe exacerbation of chronic obstructive pulmonary dis-
ease (COPD) is defined as an acute worsening of chronic
respiratory symptoms and decompensated respiratory
acidosis [1]. In the case of hypercapnic acute respiratory
failure (ARF), the sole optimization of standard medical
therapy may fail in up to 74% of patients [2]. In addition
to pharmacological therapy, recent guidelines recommend
the use of noninvasive ventilation (NIV) in the absence of
metabolic causes of acidosis [1, 3]. Indeed, NIV improves
vital signs and gas exchanges [2, 4], increasing alveolar
ventilation [5]. NIV also reduces the patient’s effort [6],
dyspnea [2, 7], the need for intubation [2, 8, 9], the inten-
sive care unit (ICU) length of stay [9] and the mortality
rate [2, 9, 10]. However, there are several determinants for
NIV success, including comfort related to the interface
and patient–ventilator interaction [4, 11–18].
High-flow nasal therapy (HFNT) is a more recent
treatment, which delivers a heated and humidified air–
oxygen mixture at high flow (up to 60 L/min) through
large-bore nasal cannula [19, 20]. Compared to standard
oxygen therapy, HFNT washes out the anatomical dead
space of the upper airway, generates a certain amount of
expiratory pharyngeal pressure proportional to the flow,
which increases the end-expiratory lung volume, slows
the respiratory rate by decreasing the respiratory time
[21], promotes the clearance of tracheobronchial secre-
tions and reduces the inspiratory effort [22–24].
While a large body of evidence is already supporting
the use of HFNT in critically ill patients with hypoxemic
ARF [23, 25–28], few studies have evaluated its effective-
ness in COPD patients [20]. In stable COPD patients,
HFNT reduces the respiratory rate [29] and the arterial
partial pressure of carbon dioxide (PaCO2) [29, 30], in-
creases the tidal volume and the end-expiratory lung
volume [29], and reduces the work of breathing and the
rapid shallow breathing pattern [31, 32]. In patients
recovering from an episode of hypercapnic ARF due to
COPD exacerbation, the respiratory rate and drive
significantly increase with standard oxygen at NIV
discontinuation, while not with HFNT [33]. Further-
more, HFNT guaranteed optimal comfort [22, 34].
A recent prospective observational trial enrolling 92
patients with severe COPD exacerbation and moderate
hypercapnic acute respiratory failure found no difference
in 30-day mortality and the intubation rate between
HNFT and NIV [34]. Currently, no randomized con-
trolled trials have compared the efficacy of HFNT with
that of NIV as first-line treatment in exacerbated COPD
patients.
We conceived the present protocol in order to evalu-
ate whether HFNT is noninferior to NIV in reducing




This is an investigator-initiated, unblinded, multicenter, non-
inferiority, randomized controlled trial. Randomization has
been achieved using a computer-generated randomization
sequence, generated by an independent investigator not
otherwise involved in the trial, with an allocation ratio of 1:1
and with a permuted block method. A single randomization
list was created for all participants. Allocation concealment
has been maintained by using sequentially numbered sealed
opaque envelopes. Each envelope contains the allocation of
the patient to either control (NIV) or intervention (HFNT),
with a unique patient identifier code. The randomization is
based on a centralized phone call system. Due to the re-
search design, neither the individual collecting data nor the
patient can be blinded to treatment allocation.
The study was prospectively registered with Clinical-
Trials.gov in December 2017 (identifier: NCT03370666).
This protocol has been designed in accordance with the
Standardized Protocol Items: Recommendations for
Interventional Trials (SPIRIT) guidelines and checklist
(Additional file 1). A schedule for enrolment, interven-
tion and assessment (SPIRIT figure) is outlined in Fig. 1.
A CONsolidated Standards of Reporting Trials (CON-
SORT) diagram is shown in Fig. 2.
Setting
The study will be conducted in the emergency department,
ICU or respiratory unit of the following Italian centers:
“Mater Domini” Hospital; “Magna Graecia” University,
Catanzaro; Policlinico “Paolo Giaccone”, University of
Palermo; University Hospital of Udine; S. Donato Hospital,
Arezzo; “S. Maria della Misericordia” Hospital, Perugia;
and “Città della Salute e della Scienza” University Hospital,
Torino. The study protocol has been prospectively ap-
proved by the local ethical committees. Further centers
have recently submitted the study protocol for ethical com-
mittee approval.
Study population
We will consider eligible consecutive adult (i.e. ≥ 18
years/old) patients with a diagnosis of COPD according
to the GOLD criteria [1] admitted for an acute-on-
chronic respiratory failure due to exacerbation, with
arterial pH between 7.25 and 7.35 and PaCO2 ≥ 55
mmHg, to the emergency department or ICU or respira-
tory unit of the participating centers. Written informed
consent will be acquired before the patient’s inclusion.
Patients will be excluded if they meet one or more of
the following criteria: already received HFNT or NIV,
prior to study enrolment; long-term domiciliary NIV;
clinical instability, as defined by the need for vasopres-
sors, acute coronary syndrome or life-threatening ar-
rhythmias [35]; treatment refusal; agitation, as defined
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by Richmond Agitation Sedation Scale (RASS) score ≥ 2,
or lack of collaboration, as defined by Kelly Matthay
score ≥ 5 [35]; acute failure of more than two organs
[35]; cardiac arrest; respiratory arrest deeming immedi-
ate intubation; recent trauma or bursts on the neck or
face; pregnancy; consent withdrawal; and enrolment in
other research protocols. The study flow chart is shown
in Fig. 2.
Intervention group
Patients randomized to the intervention group will re-
ceive HFNT (Optiflow and MR850 or AIrVO2™; Fisher
& Paykel Healthcare, Auckland, New Zealand), initially
set at 60 L/min and a temperature of 37 °C. In the case
of discomfort, the flow and/or temperature will be
downregulated to the most tolerated setting. In the
HFNT group, a rescue NIV treatment will be allowed in
the case of worsening of respiratory failure and/or treat-
ment failure, before proceeding with an eventual endo-
tracheal intubation and invasive mechanical ventilation.
Control group
Patients randomized to the control group will receive NIV
applied through a total full-face or oro-nasal mask. The ven-
tilator will be set in pressure support ventilation (PSV)
mode, with positive end-expiratory pressure (PEEP) between
3 and 5 cmH2O. The inspiratory pressure support will be
regulated in order to achieve a measured or estimated tidal
volume equal to 6–8ml/kg of ideal body weight [35]. The
Fig. 1 A schedule for enrolment, intervention and assessment according to the Standard Protocol Items: Recommendations for Interventional Trials
(SPIRIT) indications. HFNT high-flow nasal therapy through nasal cannula, ICU intensive care unit, NIV noninvasive ventilation
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treating physicians, based on local availability, will choose
the ventilators used to deliver NIV.
In both groups, treatment other than ventilatory
support will be supplied according to current guide-
lines [1]. Sedatives will be allowed to improve the pa-
tient’s comfort and tolerance of the interfaces. The
inspired oxygen fraction (FiO2) will be set to maintain
a peripheral saturation (SpO2) target between 88 and
92% [1]. In the case of treatment interruption due to
any reason, patients will receive oxygen supply
through a Venturi mask to achieve the same SpO2
target. During study interventions, patients will be
monitored by at least continuous SpO2, electrocardio-
gram and noninvasive blood pressure.
Study endpoints
The primary endpoint of the study will be to evaluate
whether HFNT is noninferior to NIV in reducing
PaCO2, at 2 h after the group allocation, in patients with
exacerbation of COPD and mild-to-moderate respiratory
acidosis. The secondary endpoints will be: noninferiority
of HFNT to NIV in reducing PaCO2 at 6 h after
randomization; dyspnea score; treatment failure rate;
discomfort related to the interface or to symptoms
Fig. 2 Study flow chart according to CONsolidated Standards of Reporting Trials. COPD chronic obstructive pulmonary disease, HFNT high-flow
nasal therapy through nasal cannula, ICU intensive care unit, NIV noninvasive ventilation, PaCO2 arterial partial pressure of carbon dioxide
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related to airway and mouth dryness; respiratory rate;
need for endotracheal intubation; time spent under
mechanical ventilation (both invasive and NIV); ICU
and hospital length of stay; and hospital mortality.
Data collection and outcome assessment
For each patient, we will collect anthropometric data
(age, gender, weight and height) and baseline character-
istics (the Simplified Acute Physiology Score (SAPS II),
the Kelly-Matthay score [36], the Charlson index [37]
and the Richmond Agitation Sedation Scale (RASS)
score [38]). Furthermore, soon before randomization we
will record vital parameters (heart rate, blood pressure,
breath frequency and temperature), the amount of secre-
tions, the presence of dyspnea (as reported by the pa-
tient through the Borg scale) [39] and arterial blood
gases (ABGs) at patient inclusion.
At 2 and 6 h after the patient’s randomization to re-
ceive NIV or HFNT, we will collect all vital parameters,
ABGs, the RASS score, the Kelly-Matthay score [36], the
grade of dyspnea and the need for sedatives. Sedation
will be allowed to increase tolerance to the treatment
[40, 41]. Moreover, we will record: the settings of NIV
and HFNT; the discomfort related to the interface, as
assessed through a 11-point Numeric Rating Scale
(NRS) [15, 42, 43]; and the intolerance to the interface
due to flow, temperature, noise, claustrophobia, sweat-
ing, tightness, airway dryness, vomiting gastric disten-
sion, ocular irritation or skin breakdown, separately [42,
44, 45].
We will also record: the rate of treatment intolerance,
as defined by the inability of the patient in continuing
NIV or HFNT treatment; the rate of treatment failure,
as defined by the presence of PaCO2 worsening or re-
duction < 10mmHg from baseline assessment, or wors-
ening or no improvement of dyspnea, or respiratory
rate > 30 breaths/min; need for endotracheal intubation;
time spent under mechanical ventilation (both invasive
and NIV); ICU and hospital length of stay; and hospital
mortality.
The decision to intubate the patient will be taken by the
physician in charge of the patient, in the case of the pres-
ence of one of the following criteria: respiratory arrest, re-
spiratory apnea or pauses with loss of consciousness,
severe agitation, bradycardia (< 50 beats/min) with loss of
consciousness, hemodynamic instability with systolic ar-
terial pressure < 70mmHg, need for invasive mechanical
ventilation due to worsening in arterial blood gases and
pH, need for suctioning due to unmanageable secretions
or intolerance to all of the interfaces (including shift of
treatment to NIV in the HFNT group).
Data will be collected on a dedicated case report form
that will be sent to the data manager in de-identified
form. The data manager will be responsible for entering
data into a dedicated database, to code and store them.
Treatment allocation will also be processed in order for
the independent investigator in charge of the statistical
analysis to be blinded.
Statistical analysis
For the purpose of the study, we computed a sample size
of 56 patients, given an α error of 5% (one-sided) and a
β error of 80%, with a standard deviation for the primary
outcome equal to 15 mmHg and a noninferiority limit of
10 mmHg [35]. After considering potential drop-outs
(30%) [35] and an increase in sample size for nonpara-
metric analysis (15%), the final computed sample size
was 80 patients (40 per group).
An independent investigator, blinded to treatment al-
location, will undertake all statistical analyses on an
intention-to-treat basis. After checking the Gaussian dis-
tribution, continuous data will be presented as mean
(standard deviation) or median (25th–75th IQR).
Categorical data will be expressed as count and per-
centage. Continuous data will be compared by the
Mann–Whitney U test or the Student t test, and cat-
egorical data by the chi-square test or the Fisher exact
test [46]. The Kruskal–Wallis test will be used to check
between-group differences at baseline, 2 h and 6 h. Fried-
man’s test or repeated-measures ANOVA will be used to
check within-group differences at different time points.
p < 0.05 will be considered significant.
Study organization
The steering committee consists of two principal investi-
gators (AC, FL) plus six members with recognized ex-
pertise on NIV/HFNT in COPD patients. The steering
committee invited other centers based on expertise and
availability of study patients and materials. Each partici-
pating center has a local principal investigator in charge.
They act as the guarantors of the data, and are respon-
sible for data management and storage in their centers.
Local principal investigators also communicate with the
principal investigators and transfer patient data in an
anonymized form on standard case report forms; in the
case of logistic difficulties or study doubts, the local in-
vestigators can ask for immediate phone call support
from principal investigators, to achieve adequate partici-
pant enrolment. Data monitoring will be done by an
ndependent investigator serving as the data manager.
This will be done by means of queries on the final
databases, after collecting the case report forms from
enrolling centers, to check for abnormalities and
inconsistencies.
Discussion
HFNT is increasingly used in different settings [23, 25–27].
Some studies indicate that HFNT has physiological
Cortegiani et al. Trials          (2019) 20:450 Page 5 of 8
advantages in both stable and exacerbated COPD patients
[20]; in particular, in patients recovering from an episode of
hypercapnic ARF due to COPD exacerbation, HFNT re-
duces the respiratory effort and rate no differently from
NIV, while it maintains similar gas exchanges and improved
comfort [22]. A recent observational trial found no differ-
ence between NIV and HNFT in terms of 30-day mortality
and intubation rate in severe exacerbation of COPD [34].
Currently, NIV is strongly suggested as standard treat-
ment for exacerbated COPD patients with respiratory
acidosis [3]. However, NIV is affected by several draw-
backs such as reduced comfort and poor patient–ventila-
tor interaction and synchrony, which is often difficult to
be recognized and managed [4, 11–13, 16]. We therefore
design this randomized controlled trial to assess the
noninferiority of HFNT in reducing the PaCO2, as com-
pared to NIV. In fact, whenever the trial demonstrates a
noninferiority of HFNT compared to NIV, the physician
may use HFNT as an alternative ventilatory support in
exacerbated COPD patients with mild-to-moderate re-
spiratory acidosis. This would also allow the possibility
to use another support with a different interface in a ro-
tational strategy to improve the patient’s comfort and
tolerance to the treatment [47, 48]. This trial has limita-
tions. First, blinding is not possible due to the nature of
the interventions. Second, although recruitment centers
have established experience in the use of ventilator sup-
port in this patient population, different practices in the
use of both NIV and HNFT may influence the effect of
the interventions. However, recruitment centers have
established experience in the use of ventilator support in
this patient population. Third, the study is a noninferior-
ity trial with a physiologic outcome, leaving uncertainty
on stronger patient-related outcomes. It is anticipated
that the results of this study will be used to design fur-
ther randomized clinical trials powered to assess major
clinical outcomes.
Trial status
The study is currently recruiting patients. The protocol
was approved by the Ethics Committee of the coordin-
ation center on 24 October 2017 (“Comitato Etico
sezione Area Centro—N°245”). The first patient was en-
rolled on 13 March 2018. Recruitment is expected to be
completed within June 2020.
Additional file
Additional file 1: SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents (DOC 122 kb)
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